This document discusses data integrity in the pharmaceutical industry. It emphasizes that data must be of known and documented quality, representative, comparable, complete, and defensible for its intended purpose. Regulations like 21CFR 58.130(e) establish standards for data quality. Maintaining integrity can be complex due to human factors like incentives, justifications, and opportunities that may compromise integrity over time. Thorough training, a culture of open reporting, and root cause analysis of issues are important to ensure integrity. Verification of data governance is also crucial throughout the supply chain.